---
title: "KAISA GROUP's revenue in the first half of the year was 3.7 billion yuan, with a net loss of 10.03 b"
description: "KAISA GROUP's revenue in the first half of the year was 3.7 billion yuan, with a net loss of 10.03 billion yuan in the first half of the year"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255001836.md"
published_at: "2025-08-28T12:03:10.000Z"
---

# KAISA GROUP's revenue in the first half of the year was 3.7 billion yuan, with a net loss of 10.03 b

> KAISA GROUP's revenue in the first half of the year was 3.7 billion yuan, with a net loss of 10.03 billion yuan in the first half of the year

In the first half of the year, KAISA GROUP reported revenue of 3.7 billion yuan and a net loss of 10.03 billion yuan

### Related Stocks

- [01638.HK - KAISA GROUP](https://longbridge.com/en/quote/01638.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Kaisa Extends Consent Solicitation Deadline for Outstanding Notes | Kaisa Group Holdings Ltd. has extended the deadline for its consent solicitation regarding outstanding notes from Februa | [Link](https://longbridge.com/en/news/275140188.md) |
| S’porean professor beats Chinese New Year travel rush to return from China for reunion dinner | Dr. Samuel Gan, a Singaporean professor at Wenzhou-Kean University, traveled over 5,000 km from China to Singapore for t | [Link](https://longbridge.com/en/news/276047662.md) |
| Beijing Haizhi Technology Announces Final Offer Price | Beijing Haizhi Technology Group Co Ltd:FINAL OFFER PRICE HK$27.06 PER H SHARE UNDER GLOBAL OFFERING | [Link](https://longbridge.com/en/news/275780031.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.